Back to Peptide Database
CognitiveFDA Approved

Semax

Overview

A synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotective properties. Semax modulates BDNF and NGF expression, enhances monoaminergic neurotransmission, and provides neuroprotection through anti-oxidant and anti-inflammatory mechanisms. It crosses the blood-brain barrier via intranasal administration.

Key Research Findings

Approved in Russia and Ukraine for treatment of stroke, cognitive disorders, and optic nerve disease. Clinical studies demonstrated improved memory, attention, and cognitive performance. Research shows upregulation of BDNF and trkB expression in the hippocampus and cortex.

Route of Administration

Intranasal

Regulatory Status

FDA Approved

Interested in Semax?

Find a verified provider experienced with Semax protocols in your area. All providers are credentialed and use compliant sourcing.

Find a Semax Provider